CAJ | 학술논문

目的：比较血清胰蛋白酶原-2与CA199对胰腺癌诊断价值。方法选取中国人民解放军北京军区总医院、石景山医院诊为胰腺癌未经治疗的患者25例；对照组随机选取体检中心健康体检者35例。入组者均留取血清标本，采用ELISA法半定量检测血清胰蛋白酶原-2、CA199的含量。结果胰腺癌组患者血清胰蛋白酶原-2中位数为13.2μg/L，四分位间距为2.25~49.15μg/L，CA199中位数为211.6μg/L，四分位间距为42~326.7μg/L，对照组血清胰蛋白酶原-2中位数为0.8μg/L，四分位间距为0.6~1.2μg/L， CA199中位数为12.8μg/L，四分位间距为6.7~26.4μg/L。以1.85 ng/ml为临界值，此时血清胰蛋白酶原-2鉴别胰腺癌与正常人的敏感度和特异度分别为96%和91.4%，ROC曲线下的面积为0.988。以37.2 U/mL为临界值，CA199鉴别诊断胰腺癌与正常人的敏感度为88%，特异度为82.9%，ROC曲线下的面积为0.906，两者ROC曲线下面积差异无统计学意义。结论血清胰蛋白酶原-2与CA199诊断胰腺癌价值差异无统计学意义，可作为一种非侵入性筛选试验,为临床联合肿瘤标志物筛查胰腺癌提供了手段。
목적：비교혈청이단백매원-2여CA199대이선암진단개치。방법선취중국인민해방군북경군구총의원、석경산의원진위이선암미경치료적환자25례；대조조수궤선취체검중심건강체검자35례。입조자균류취혈청표본，채용ELISA법반정량검측혈청이단백매원-2、CA199적함량。결과이선암조환자혈청이단백매원-2중위수위13.2μg/L，사분위간거위2.25~49.15μg/L，CA199중위수위211.6μg/L，사분위간거위42~326.7μg/L，대조조혈청이단백매원-2중위수위0.8μg/L，사분위간거위0.6~1.2μg/L， CA199중위수위12.8μg/L，사분위간거위6.7~26.4μg/L。이1.85 ng/ml위림계치，차시혈청이단백매원-2감별이선암여정상인적민감도화특이도분별위96%화91.4%，ROC곡선하적면적위0.988。이37.2 U/mL위림계치，CA199감별진단이선암여정상인적민감도위88%，특이도위82.9%，ROC곡선하적면적위0.906，량자ROC곡선하면적차이무통계학의의。결론혈청이단백매원-2여CA199진단이선암개치차이무통계학의의，가작위일충비침입성사선시험,위림상연합종류표지물사사이선암제공료수단。
Objective To compare diagnostic value of serum trypsinogen-2 and CA199 in pancreatic cancer.Methods A total of 60 fresh serum samples were collected from the patients, including 25 cases of pancreatic cancer, 35 cases of normal control, detect the level of serum of trypsinogen-2 and CA199 by ELISA. ResultsThe median level of serum trypsinogen-2 was 0.8μg/L in the controls, interquartile Range was 0.6~1.2 μg/L, 13.2 μg/L and 2.25~49.15 μg/L in pancreatic cancer. The median level of serum CA199 was 12.8μg/L in the controls, interquartile Range was 6.7~26.4 μg/L, 211.6μg/L and 42~326.7μg/L in pancreatic cancer. The sensitivity and speciifcity for differentiation between pancreatic cancer and control group was 91.4%, 96%, respectively, the area under the ROC curve was 0.989. It was 88% and 82.9%, 0.906 for CA199. There was no statistically differences between the area of ROC curve of trypsinogen-2 and C199.Conclusion There was no statistically differences between the area of ROC curve of trypsinogen-2 and C199 in diagnosis of pancreatic cancer. As a non-invasive screening test, detection of serum trypsinogen-2 can be used to combined tumer markers in screen prophase pancreatic cancer.